市场调查报告书
商品编码
1587759
2030 年尼古丁口香糖市场预测:按产品、分销管道、最终用户和地区分類的全球分析Nicotine Gum Market Forecasts to 2030 - Global Analysis by Product (Regular Nicotine Gum, Sugar-Free Nicotine Gum and Flavored Nicotine Gum), Distribution Channel, End User and By Geography |
根据 Stratistics MRC 的数据,2024 年全球尼古丁口香糖市场规模为 17.4 亿美元,预计在预测期内复合年增长率为 7.1%,到 2030 年将达到 26.3 亿美元。
尼古丁口香糖是一种尼古丁替代疗法 (NRT),可以帮助您戒烟并减少对香烟的渴望。无糖口香糖,尼古丁含量适中,有助于调节与尼古丁成瘾相关的渴望和戒断症状。咀嚼口香糖会释放尼古丁,尼古丁会透过口腔黏膜吸收,成为抑制烟瘾的快速而简单的方法。作为全面戒烟计画的一部分,各种口味和浓度的尼古丁口香糖经常被用来鼓励选择健康的生活方式并促进从传统烟草产品的过渡。
提高戒烟意识
提高戒烟意识对尼古丁口香糖业务产生重大影响,因为它鼓励吸烟者寻求有效的戒烟方法。由于强调吸烟风险并支持尼古丁替代疗法的公共卫生宣传活动,尼古丁口香糖等产品越来越受欢迎。随着人们更了解戒烟的好处以及可帮助他们戒烟的资讯来源,对尼古丁口香糖的需求也在增加。最终,这一趋势为想要戒烟的吸烟者创造了友善的氛围,从而有助于扩大市场。
消费者焦虑
消费者对尼古丁口香糖的担忧源自于对依赖、潜在副作用的恐惧以及对功效的误解。有些人可能对采用替代疗法持谨慎态度,或者可能更喜欢更传统的戒烟方法。儘管尼古丁口香糖在帮助人们戒烟和控制烟瘾方面已被证明具有益处,但潜在消费者可能会迴避它,从而可能阻碍市场扩张。
政府倡议
政府行动透过制定降低吸烟率的政策,对塑造尼古丁口香糖市场有重要影响。对公共卫生宣传活动和戒烟计画的资助将增加人们对口香糖等尼古丁替代疗法的了解。提高捲烟价格和限制广告等法规鼓励吸烟者寻找替代品。透过在尼古丁口香糖周围营造积极的氛围,这些努力鼓励想要戒烟的人使用尼古丁口香糖并改善整体公共卫生。从而促进了市场的成长。
监管挑战
监管挑战透过对行销、标籤和分销制定严格的要求,对尼古丁口香糖市场产生了重大影响。这些规则可能会限制某些人群的访问或限制促销活动。此外,不同地区的不同法规可能使营运商更难以遵守并阻碍市场扩张。这些困难可能会阻碍寻求有效戒烟辅助的使用者对尼古丁口香糖的吸收。
由于健康问题促使许多人戒烟,COVID-19 大流行提振了尼古丁口香糖市场。人们对呼吸系统健康的认识提高以及尼古丁替代疗法的可用性导致需求激增。此外,电子商务的发展使尼古丁口香糖更容易取得,消费者可以谨慎购买。总体而言,这场大流行加速了吸烟者转向更健康的替代品。
在预测期内,药房/药局行业预计将是最大的。
由于药局/药局是值得信赖的医疗保健提供者,消费者将越来越多地寻求戒烟协助,预计这将是预测期内最大的市场。此外,药局经常透过健康宣传活动来推销尼古丁口香糖,提高认知度和销售量。拥有知识丰富的员工可以提供正确使用的指导并增强消费者的信心。总体而言,药局是重要的分销管道,对市场成长产生重大影响并支持公共卫生工作。
无糖尼古丁口香糖细分市场预计在预测期内复合年增长率最高
无糖尼古丁口香糖部分预计在预测期内表现出最高的复合年增长率,因为这种成分降低了牙齿问题的风险,并提供了一种无罪恶感的戒烟选择。它的日益普及补充了更大的健康趋势,并有助于戒烟。砂糖选择的出现也将吸引年轻消费者,进而扩大市场规模。总体而言,这项创新改善了客户的福祉,并有助于提高对尼古丁替代疗法的认识。
预计北美在预测期内将占据最大的市场占有率。这与政府遏止烟草使用的努力是一致的,因为增加烟草的供应和认识有助于健康的生活方式。从经济角度来看,市场成长是透过创造就业机会和产品开拓创新来推动的。此外,透过满足对替代尼古丁输送方法不断增长的需求并满足不同的消费者偏好,我们最终将促进整个全部区域减少烟草依赖的转变。
由于人们对戒烟选择的认识不断提高以及对健康问题的日益关注,预计亚太地区在预测期内的复合年增长率最高。随着各国实施更严格的烟草禁令,尼古丁口香糖等替代方案的市场正在扩大。电子商务的兴起和注重健康的消费者的崛起也推动了市场扩张。由于产品口味和配方的创新吸引了广泛的消费者,尼古丁口香糖已成为首选的戒烟选择。
According to Stratistics MRC, the Global Nicotine Gum Market is accounted for $1.74 billion in 2024 and is expected to reach $2.63 billion by 2030 growing at a CAGR of 7.1% during the forecast period. Nicotine gum is a type of nicotine replacement therapy (NRT) that helps people quit smoking or lessen tobacco cravings. It is a sugar-free chewing gum with a moderate nicotine content that helps users regulate cravings and withdrawal symptoms related to nicotine addiction. Chewing the gum releases and absorbs nicotine through the mouth's lining, making it a quick and easy approach to quell cravings. As part of a comprehensive smoking cessation program, nicotine gum-which comes in a variety of flavors and strengths-is frequently used to encourage healthy lifestyle choices and facilitate the shift away from traditional tobacco products.
Increasing Smoking Cessation Awareness
Raising awareness of smoking cessation has a substantial impact on the nicotine gum business because it encourages smokers to seek effective ways to quit. Products like nicotine gum become more popular as a result of public health campaigns that emphasize the risks of smoking and support nicotine replacement treatments. The demand for nicotine gum increases as people learn more about the advantages of quitting and the resources available to help them do so. In the end, this trend propels market expansion by creating a friendly atmosphere for smokers wishing to quit using tobacco.
Consumer Reluctance
Consumer apprehension regarding nicotine gum arises from fears about dependence, potential side effects, and misconceptions about its efficacy. Some people might be wary of employing replacement therapy or prefer more conventional ways of quitting. Despite nicotine gum's demonstrated advantages in helping people quit smoking and controlling cravings, potential consumers may shun it, which could impede market expansion.
Government Initiatives
Government actions play an important influence in shaping the nicotine gum market by enacting policies to reduce smoking rates. Funding for public health campaigns and smoking cessation programs raise knowledge of nicotine replacement treatments like gum. Smokers are encouraged to look for alternatives by regulations like increased tobacco pricing and limitations on advertising. By fostering a positive atmosphere around nicotine gum, these initiatives encourage those who want to stop smoking to use it and enhance public health in general. Thus, it boosts the growth of the market.
Regulatory Challenges
Regulatory challenges have a huge impact on the nicotine gum market by setting rigorous requirements for marketing, labeling, and distribution. These rules may restrict access to specific demographics and limit promotional activity. Furthermore, different regional restrictions could make it more difficult for businesses to comply, which would impede their ability to expand their market. These difficulties may hinder the uptake of nicotine gum by users looking for efficient smoking cessation products.
The COVID-19 pandemic boosted the nicotine gum market as health concerns prompted many to quit smoking. Increased awareness of respiratory health and the availability of nicotine replacement therapies led to a surge in demand. Additionally, e-commerce growth facilitated access to nicotine gum, allowing consumers to purchase discreetly. Overall, the pandemic accelerated the shift towards healthier alternatives among smokers.
The pharmacies/drug stores segment is expected to be the largest during the forecast period
The pharmacies/drug stores segment is expected to be the largest during the forecast period as their trusted status as healthcare providers encourages consumers to seek assistance in quitting smoking. Additionally, pharmacies often promote nicotine gum through health campaigns, increasing awareness and sales. The presence of knowledgeable staff can offer guidance on proper usage, enhancing consumer confidence. Overall, pharmacies serve as vital distribution channels, significantly impacting the market's growth and supporting public health initiatives.
The sugar-free nicotine gum segment is expected to have the highest CAGR during the forecast period
The sugar-free nicotine gum segment is expected to have the highest CAGR during the forecast period because this composition lowers the risk of tooth problems and provides a guilt-free smoking cessation option. Its rising popularity complements larger health trends and aids with smoking cessation attempts. The market reach is increased by the availability of sugar-free choices, which also draw in younger consumers. All things considered, this innovation improves customer happiness and helps to improve the way that nicotine replacement treatments are perceived.
North America is projected to hold the largest market share during the forecast period because increased accessibility and awareness contribute to healthier lifestyles, aligning with government initiatives to curb tobacco use. Economically, the market fosters growth through job creation and innovation in product development. Moreover, it addresses the rising demand for alternative nicotine delivery methods, catering to diverse consumer preferences and ultimately promoting a shift towards reduced tobacco dependence across the region.
Asia Pacific is projected to witness the highest CAGR over the forecast period due to increased awareness of smoking cessation options and growing health concerns. The market for substitutes like nicotine gum is increasing as nations impose more stringent tobacco prohibitions. Market expansion is also being aided by the rise of e-commerce and an increasing number of health-conscious consumers. Nicotine gum is becoming a well-liked option for quitting smoking because to innovations in product tastes and formulations that is drawing in a wider range of consumers.
Key players in the market
Some of the key players in Nicotine Gum Market include Altoids (Wrigley), Cambridge Research Biochemicals, Cipla Limited, Dr. Reddy's Laboratories, GlaxoSmithKline (GSK), Hero Group, Johnson & Johnson (McNeil Consumer Healthcare), Nicorette, Novartis AG, Pfizer Inc., Purdue Pharma L.P., QuitX, Reynolds American Inc. (R.J. Reynolds Tobacco Company), Smoke-Free Tobacco Products, LLC, Sundown Naturals and Swedish Match AB.
In June 2024, Orchid Pharma has partnered with Cipla Limited to ensure widespread and rapid distribution of this breakthrough antibiotic combination across India.
In June 2024, Cipla Limited has signed a non-exclusive Patent License agreement with Takeda Pharmaceutical Company Limited for 'Vonoprazan' for India Market for treating acid-related illnesses among patients.
In March 2024, Sanofi Healthcare India Private Limited and Cipla Limited announced an exclusive partnership for distribution and promotion of Sanofi India's Central Nervous System (CNS) product range in India.